1. Rath T, Rubbert A. Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol. 2010;28:S52–7.
2. Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med. 2008;168:378–81.
3. Gaulard P, Swerdlow SH, Harris NL, et al. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al. editors. World Health Organization classification of tumours of hematopoietic and lymphoid tissue. Revised 4th edn. Lyon, France: International Agency of Research on Cancer; 2017. p. 462–4.
4. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88:497–502.
5. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996;32a:1753–7.